

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫療控股有限公司

China Resources Medical Holdings Company Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

- (1) RETIREMENT OF EXECUTIVE DIRECTOR;**
(2) CHANGE OF CHAIRMAN OF THE BOARD AND
AUTHORISED REPRESENTATIVE;
(3) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS;
AND
(4) CHANGE OF COMPOSITION OF BOARD COMMITTEES

The Board hereby announces that with effect from June 19, 2025: (1) Mr. SONG Qing has retired as an executive Director, the chairman of the Board, the chairman of the Nomination Committee and the Authorised Representative; (2) Mr. YU Hai has been appointed as the chairman of the Board, the chairman of the Nomination Committee and the Authorised Representative; (3) Mr. KWONG Kwok Kong has retired as an independent non-executive Director, the chairman of the Audit Committee and a member of the Nomination Committee; (4) Ms. LO Wing Sze has been appointed as an independent non-executive Director, a member of the Audit Committee and a member of the Nomination Committee; and (5) Mr. FU Tingmei has been appointed as the chairman of the Audit Committee.

**RETIREMENT OF EXECUTIVE DIRECTOR, CHAIRMAN OF THE BOARD,
CHAIRMAN OF THE NOMINATION COMMITTEE AND AUTHORISED
REPRESENTATIVE**

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Resources Medical Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. SONG Qing (“**Mr. SONG**”) has notified the Board of his plan of retirement, and retired as an executive Director, the chairman of the Board and the chairman of the nomination committee of the Company (the “**Nomination Committee**”) and cessation to act as an authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) with effect from June 19, 2025. Mr. SONG has confirmed that he has no disagreement with the Board and that there is no matter in respect of his retirement which needs to be brought to the attention of the shareholders of the Company (the “**Shareholder(s)**”) and the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board hereby expresses its gratitude to Mr. SONG for his valuable efforts and contributions to the Group during his tenure of office as an executive Director, the chairman of the Board, the chairman of the Nomination Committee and the Authorised Representative.

APPOINTMENT OF CHAIRMAN OF THE BOARD, CHAIRMAN OF THE NOMINATION COMMITTEE AND AUTHORISED REPRESENTATIVE

The Board is pleased to announce that Mr. YU Hai (“**Mr. YU**”), an executive Director and the chief executive officer of the Company (the “**Chief Executive Officer**”), has been appointed as the chairman of the Board, the chairman of the Nomination Committee and the Authorised Representative with effect from June 19, 2025.

Mr. YU Hai, aged 57, joined the Group in February 2023 as an executive Director and the Chief Executive Officer. He is currently the chairman of China Resources Healthcare Group Limited (“**CR Healthcare**”) which is an indirect controlling shareholder of the Company. Mr. YU served as the vice-chairman, the general manager and the senior vice general manager of CR Healthcare from January 2020 to June 2025 and as the chairman of Liaoning Healthcare Industry Group Co., Ltd. from July 2018 to January 2020. Mr. YU worked in Benxi Municipal Government, Liaoning Province from July 2008 to July 2018, and served as the deputy mayor of Benxi City etc. Prior to that, Mr. YU held various positions at government departments including the deputy director of the Social Development Division of the Department of Science & Technology of Liaoning Province, the deputy director of the High-tech Development and Industrialization Division of the Department of Science & Technology of Liaoning Province, the deputy director of the Bureau of Science and Technology of Nagchu District, the Tibet Autonomous Region, and the principal officer of the Industrial and Social Development Division, the Scientific and Technological Commission of Liaoning Province etc.. Mr. YU holds a doctor of science degree in pharmaceutical affairs management from the School of Pharmacy, Shenyang Pharmaceutical University.

Mr. YU has entered into a service agreement with the Company for a term of three years for his position as an executive Director, commencing from February 27, 2023 to February 26, 2026 and subject to termination before expiry by either party giving not less than one month’s notice in writing to the other. He is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. Mr. YU does not receive any director’s fee from the Company, but he is entitled to receive remuneration from the Company by taking up other positions. The emolument of Mr. YU will be determined by the Board, upon recommendation by the remuneration committee of the Company (the “**Remuneration Committee**”) with reference to the prevailing market situation and his duties and responsibilities to the Group. He shall be entitled to the discretionary bonus at the sole and absolute discretion of the Board and the Remuneration Committee which shall be determined with reference to the Board’s corporate goals and objectives, salaries paid by comparable companies, time commitment, responsibilities, employment conditions and performance of the Company and the individual Director.

As at the date of this announcement, Mr. YU does not have any interests in the shares or underlying shares of the Company and/or the associated corporations of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “SFO”).

Save as disclosed in this announcement, Mr. YU (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

Save as disclosed in this announcement, there is no further information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to the appointment of Mr. YU that needs to be brought to the attention of the Shareholders and the Stock Exchange.

The Board hereby expresses its warmest welcome to Mr. YU for the new appointments.

RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, CHAIRMAN OF THE AUDIT COMMITTEE AND MEMBER OF THE NOMINATION COMMITTEE

The Board hereby announces that Mr. KWONG Kwok Kong (“**Mr. KWONG**”) has notified the Board of his plan of retirement, and retired as an independent non-executive Director, the chairman of the audit committee of the Company (the “**Audit Committee**”) and a member of the Nomination Committee with effect from June 19, 2025. Mr. KWONG has confirmed that he has no disagreement with the Board and that there is no matter in respect of his retirement which needs to be brought to the attention of the Shareholders and the Stock Exchange.

The Board hereby expresses its gratitude to Mr. KWONG for his valuable efforts and contributions to the Group during his tenure of office as an independent non-executive Director, the chairman of the Audit Committee and a member of the Nomination Committee.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, MEMBER OF THE AUDIT COMMITTEE AND MEMBER OF THE NOMINATION COMMITTEE

The Board is pleased to announce that Ms. LO Wing Sze (“**Ms. LO**”) has been appointed as an independent non-executive Director, a member of the Audit Committee and a member of the Nomination Committee with effect from June 19, 2025.

Ms. LO Wing Sze BBS, JP, aged 53. Ms. LO is the financial director of Million Group, and has 25 years of experience in corporate governance, tourist services and hotel management.

Ms. LO is a member of the Election Committee 2021 (The Fourth Sector) of the Hong Kong Special Administrative Region (“**HKSAR**”) and was a member of the Election Committee for the Fifth Government of the HKSAR (Tourism Subsector). She is an All-China Women’s Federation HKSAR delegate.

Ms. LO is a member of the Chief Executive's Policy Unit Expert Group, the Advisory Committee on Post-office Employment for Former Chief Executives and Politically Appointed Officials, the Advisory Committee on Admission of Quality Migrants and Professionals, the Immigration Department Users' Committee, the Correctional Services Children's Education Trust Investment Advisory Board and the District Fight Crime Committee (Wan Chai District). She is also an Honorary Court Member of the Lingnan University. Ms. LO is the chairlady of Tai Hang Fire Dragon Heritage Centre (Revitalising Historic Buildings Through Partnership Scheme Batch IV), a founding member of Hong Kong Red Cross EmpowerHer Network and a member of the Hong Kong Society of Rehabilitation Fundraising and Social Enterprise Committee.

Ms. LO is currently an independent non-executive director of China Resources Mixc Lifestyle Services Limited (stock code: 1209), New World Development Company Limited (stock code: 17), Goldlion Holdings Limited (stock code: 533) and Lee & Man Paper Manufacturing Limited (stock code: 2314), all being companies listed on the Stock Exchange. She served as an independent non-executive director of Finsoft Financial Investment Holdings Limited (a company listed on the Stock Exchange, stock code: 8018) from August 2020 to July 2023, and an independent non-executive director of Virtual Mind Holding Company Limited (a company listed on the Stock Exchange, stock code: 1520) from January 2021 to June 2025.

Ms. LO holds a bachelor of economics degree from the University of Sydney and a master of commerce in finance Degree from the University of New South Wales in Australia. She is a member of the Hong Kong Institute of Certified Public Accountants and a fellow member of CPA Australia.

Ms. LO has entered into a letter of appointment with the Company for a term of three years from June 19, 2025 to June 18, 2028 and subject to termination before expiry by either party giving not less than one month's notice in writing to the other. She is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. According to the letter of appointment, Ms. LO is entitled to director's fees of HK\$300,000 per annum, which was determined by the Board, upon recommendation by the Remuneration Committee with reference to the prevailing market situation and her duties and responsibilities to the Group.

As at the date of this announcement, Ms. LO does not have any interests in the shares or underlying shares of the Company and/or the associated corporations of the Company within the meaning of Part XV of the SFO.

Save as disclosed in this announcement, Ms. LO (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

Ms. LO has confirmed that (i) she has satisfied all the criteria for independence set out in Rule 3.13(1) to (8) of the Listing Rules; (ii) she had no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected persons of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment. Save as disclosed in this announcement, there is no further information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to the appointment of Ms. LO that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Board hereby expresses its warmest welcome to Ms. LO for her new appointments.

APPOINTMENT OF CHAIRMAN OF THE AUDIT COMMITTEE

The Board is pleased to announce that Mr. FU Tingmei (“**Mr. FU**”), an independent non-executive Director and a member of the Audit Committee, has been appointed as the chairman of the Audit Committee with effect from June 19, 2025. Upon the appointment of Mr. FU as the chairman of the Audit Committee, the Company has continued to be in compliance with Rule 3.21 of the Listing Rules which requires the Audit Committee to be chaired by an independent non-executive director.

The Board hereby expresses its warmest welcome to Mr. FU for his new appointment to become the chairman of the Audit Committee.

NON-COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

Pursuant to Code Provision C.2.1 of Part 2 of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Although Mr. YU concurrently serving as the chairman of the Board and the Chief Executive Officer will result in the Company’s deviation from Code Provision C.2.1, the Board believes that with the support of the management, vesting the duties and responsibilities of both chairman of the Board and the Chief Executive Officer by the same person can facilitate execution of the Group’s business strategies and boost effectiveness of its operation. In addition, under the supervision by the Board which currently consists of three executive Directors, one non-executive Director and four independent non-executive Directors, the interest of the Shareholders will continue to be adequately and fairly represented. In order to comply with Code Provision C.2.1, the Company is endeavouring to identify suitable candidate(s) with appropriate professional qualifications or relevant expertise to be appointed as the Chief Executive Officer as soon as practicable. The Company will make further announcement(s) in relation to the above matters as and when appropriate.

By order of the Board
China Resources Medical Holdings Company Limited
YU Hai
Chairman

PRC, June 19, 2025

As at the date of this announcement and after the aforesaid changes, the Board comprises Mr. YU Hai, Mr. SHAN Baojie and Ms. YANG Min as executive Directors; Ms. GE Lu as non-executive Director; Mr. WU Ting Yuk, Anthony, Mr. FU Tingmei, Mr. ZHOU Peng and Ms. LO Wing Sze as independent non-executive Directors.